| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss from continuing operations | -5,465 | -3,281 | 12,410 | -10,256 |
| Accelerated amortization of right-of-use asset in connection with lease abandonment | NaN | 0 | 0 | NaN |
| Loss on extinguishment of debt | NaN | 0 | 0 | 0 |
| Gain on conversion of note receivable to investment in equity securities | NaN | -825 | NaN | NaN |
| Gain on investment in equity securities | NaN | 0 | 16,580 | 0 |
| Stock-based compensation | 6,780 | 7,579 | 7,766 | 13,610 |
| Depreciation and amortization | 1,337 | 1,200 | 1,041 | 1,047 |
| Amortization of deferred contract costs | 475 | 451 | 429 | 746 |
| Amortization of debt discount and issuance costs | NaN | 0 | 0 | 0 |
| Amortization of operating lease right-of-use assets | 123 | 181 | 151 | 199 |
| Gain on sale of insurance business | NaN | 0 | 0 | NaN |
| Equity in losses of equity method investees, net of tax | -381 | NaN | NaN | NaN |
| Other | -412 | -43 | 39 | 316 |
| Trade and other receivables | 9,061 | -3,415 | -2,709 | 364 |
| Prepaid expenses and other assets, current and non-current | -1,144 | 721 | 3,447 | 1,262 |
| Deferred contract costs, non-current | -43 | 289 | -263 | 531 |
| Accounts payable | -1,599 | 1,054 | -429 | -419 |
| Deferred revenue | 14,637 | -5,940 | -7,421 | 12,734 |
| Accrued compensation | -543 | -159 | 1,650 | -684 |
| Investment in note receivable | NaN | 0 | NaN | NaN |
| Operating lease liabilities | -120 | -136 | -712 | -1,921 |
| Other | NaN | 0 | 0 | NaN |
| Other liabilities, current and non-current | -82 | -234 | -524 | 2,210 |
| Proceeds from sale of insurance business | NaN | 0 | 0 | NaN |
| Net cash provided by operating activities - continuing operations | 8,462 | 2,338 | -2,733 | 14,793 |
| Cash received in connection with conversion of note receivable to investment in equity securities | NaN | 2,255 | NaN | NaN |
| Net cash (used in) provided by operating activities - discontinued operations | -1,110 | -1,358 | -757 | -771 |
| Investment in non-marketable equity securities | NaN | 0 | 0 | 4,000 |
| Net cash provided by operating activities | 7,352 | 980 | -3,490 | 14,022 |
| Purchases of marketable securities | 4,966 | 4,995 | 6,741 | 23,749 |
| Sale of available-for-sale securities | 0 | 0 | 19,968 | 859 |
| Maturities of marketable securities | 8,000 | 2,500 | 16,500 | 27,727 |
| Additions to property, equipment and internal-use software development costs | 1,117 | 1,001 | 2,272 | 8,320 |
| Net cash provided by investing activities - continuing operations | 1,917 | -1,241 | 27,455 | -7,483 |
| Net cash provided by (used in) investing activities - discontinued operations | 970 | -13 | -62 | -120 |
| Net cash provided by investing activities | 2,887 | -1,254 | 27,393 | -7,603 |
| Repayment of long-term debt | NaN | 0 | 0 | 0 |
| Proceeds from exercises of stock options, including early exercises, net of repurchases | 96 | 147 | 712 | 793 |
| Net proceeds from the issuance of the series a redeemable convertible preferred stock and the haveli warrant | NaN | 0 | 0 | 0 |
| Taxes paid related to net share settlement of equity awards | 1,127 | 1,981 | 1,886 | 5,502 |
| Payment for issuance costs related to the series a redeemable convertible preferred stock and the haveli warrant | NaN | 0 | 0 | 0 |
| Share repurchases | 16,836 | 15,727 | 5,025 | 4,118 |
| Net cash used in financing activities | -17,867 | -17,561 | -6,199 | -8,827 |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | -5 | 0 | 0 | 0 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -7,633 | -17,835 | 17,704 | -2,408 |
| Cash, cash equivalents, and restricted cash at beginning of period | 46,998 | 64,833 | 49,537 | NaN |
| Cash, cash equivalents, and restricted cash at end of period | 39,365 | 46,998 | 64,833 | NaN |
| Less cash, cash equivalents and restricted cash included in current assets held for sale from discontinued operations | 0 | 3,420 | NaN | NaN |
| Cash, cash equivalents and restricted cash, end of period, excluding current assets held for sale from discontinued operations | 39,365 | 43,578 | NaN | NaN |
Blend Labs, Inc. (BLND)
Blend Labs, Inc. (BLND)